SAMHD1 and acute myeloid leukemia: In an independent line of investigations, SAMHD1 was found to not only degrade naturally occurring dNTPs, but also some nucleotide analogs, including cytarabine (ara-C) and decitabine (DAC), which are used for the treatment of acute myeloid leukemia (AML) (Herold et al., 2017a, Herold et al., 2017b, Hollenbaugh et al., 2017, Oellerich et al., 2019, Schneider et al., 2017).